Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04815109
Other study ID # EEG in COVID-19
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 1, 2021
Est. completion date June 30, 2022

Study information

Verified date August 2022
Source Goethe University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Sedation of severe COVID-19 disease are often complicated. We try to find a correlate for this observation by encephalographic studies.


Description:

Sedation of critically ill ventilated coronavirus patients, continues to be a challenging issue. Also, neurological symptoms of severe COVID-19 disease have been described frequently. Difficulties in sedation of these patients have been discussed repeatedly. The aim of this study is to investigate whether an encephalographic correlate can be found. Appropriate processed encephalographic techniques have been used for anesthesia monitoring for many years. The aim of our study is to collect unrelated processed and raw EEG data of sedated COVID-19 patients and to investigate the correlation to the necessary sedation.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date June 30, 2022
Est. primary completion date February 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: Intubated ventilated patients with SARS-CoV-2 associated acute respiratory distress syndrome and sedation difficulty. Exclusion Criteria: Pre-existing severe cerebral brain damage and dysfunction. For example: previous medial infarction, cerebral hemorrhage, structural epilepsy.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Encephalography measurement
Encephalography measurement and partially aggravated sedation.

Locations

Country Name City State
Germany University Hospital Frankfurt Frankfurt Hessen

Sponsors (1)

Lead Sponsor Collaborator
Goethe University

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Raw data encephalography measurement Measurement of the brain activity detectable for the examination procedure in the surface encephalogram. From the beginning of the measurement until the end of the examination (10 to 20 minutes).
Primary Processed encephalography measurement Measurement of detectable algorithm based patient sedation score based on brain activity in the surface encephalogram. From the beginning of the measurement until the end of the examination (10 to 20 minutes).
Secondary Dosage of continuously administered centrally acting alpha2 agonists. Sedative dosage continuously administered during the measurement interval. [µg/kg/h] From 90 minutes before to 10 minutes after encephalographic measurement
Secondary Dosage of continuously delivered central GABA receptor active substances. Sedative dosage continuously administered during the measurement interval. [mg/kg/h] From 90 minutes before to 10 minutes after encephalographic measurement
Secondary Dosage of continuously delivered central NMDA receptor active substances. Sedative dosage continuously administered during the measurement interval. [mg/kg/h] From 90 minutes before to 10 minutes after encephalographic measurement
Secondary Dosage of continuously delivered opioid based analgesia. Analgetic dosage continuously administered during the measurement interval. [µg/kg/h] From 90 minutes before to 10 minutes after encephalographic measurement
See also
  Status Clinical Trial Phase
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Recruiting NCT05535543 - Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
Completed NCT04695392 - Restore Resilience in Critically Ill Children N/A
Terminated NCT04972318 - Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia N/A
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Completed NCT04078984 - Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
Completed NCT04451291 - Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure N/A
Not yet recruiting NCT06254313 - The Role of Cxcr4Hi neutrOPhils in InflueNza
Not yet recruiting NCT04798716 - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19 Phase 1/Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT02881385 - Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation N/A
Terminated NCT02867228 - Noninvasive Estimation of Work of Breathing N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT02232841 - Electrical Impedance Imaging of Patients on Mechanical Ventilation N/A
Withdrawn NCT01927237 - Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide N/A
Completed NCT02889770 - Dead Space Monitoring With Volumetric Capnography in ARDS Patients N/A
Completed NCT01504893 - Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia N/A
Completed NCT01680783 - Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure N/A
Completed NCT02814994 - Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients N/A